Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?

Medical Hypotheses
Begoña Quintana-Villamandos, Emilio Delgado-Baeza

Abstract

Hypertensive left ventricular hypertrophy (LVH) is a maladaptive response to chronic pressure overload and a strong independent risk factor for cardiovascular disease. Regression of LVH is associated with improved prognosis. Regression of LVH with antihypertensive therapy (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, calcium channel blockers, and diuretics) has been reported, although only after long-term treatment. Asymmetrical dimethylarginine (ADMA), the most potent endogenous NO synthase inhibitor, is emerging as an important cardiovascular risk factor in patients with arterial hypertension and LVH, and dimethylarginine dimethylaminohydrolase (DDAH) is the mechanism that most frequently leads to accumulation of ADMA (plasma ADMA is cleared in small part by renal excretion, although the bulk of ADMA is degraded by DDAH). Left ventricular mass is strongly modulated by the NO system. As an important inhibitor of the bioavailability of NO, ADMA is an underlying mechanism of LVH. Beta-blockers can induce regression of LVH and reduced plasma ADMA levels. Oxidative stress is increased in patients with LVH, and this in turn increases generation of ADMA. In a previous preclinical study of s...Continue Reading

References

Oct 6, 1999·The Annals of Thoracic Surgery·H HorimotoI B Krukenkamp
Jun 1, 2000·Proceedings of the National Academy of Sciences of the United States of America·C J FriddleJ Bristow
Apr 2, 2002·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Tatsuyuki OnoderaSeibu Mochizuki
Jun 26, 2002·Kidney International·Carmine ZoccaliUNKNOWN CREED Investigators
Feb 20, 2003·European Journal of Pharmacology·Alexandra OudotLuc Rochette
Nov 18, 2004·JAMA : the Journal of the American Medical Association·Richard B DevereuxBjörn Dahlöf
Jan 25, 2005·American Journal of Physiology. Heart and Circulatory Physiology·Xiao-Ming GaoXiao-Jun Du
Feb 3, 2005·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Nathalie MougenotPhilippe Lechat
Feb 11, 2005·Clinical and Experimental Hypertension : CHE·Enrico Agabiti Rosei, Maria Lorenza Muiesan
Apr 22, 2006·Progress in Cardiovascular Diseases·Alan H Gradman, Fadi Alfayoumi
Feb 24, 2007·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Vivencio BarriosRaúl Fernandez
Jun 7, 2007·Pharmacology·Frank C BaroneRobert W Coatney
Apr 11, 2008·European Journal of Heart Failure·Mayu NishioKazuhiro Yamamoto
Jul 9, 2009·Basic & Clinical Pharmacology & Toxicology·David LochLindsay Brown
Aug 6, 2009·Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension·Fedor SimkoLudovit Paulis
Aug 22, 2009·The Journal of Clinical Hypertension·Wadih Nadour, Robert W W Biederman
Sep 15, 2009·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroshi KomatsuHiroyuki Tsutsui
Jan 28, 2010·Nature Reviews. Cardiology·Alberto Zanchetti
Aug 11, 2010·Hypertension·Zaiming LuoChristopher S Wilcox
Oct 29, 2010·Journal of the American Society of Hypertension : JASH·Alan B MillerGeorge L Bakris
Jul 26, 2011·Diabetic Medicine : a Journal of the British Diabetic Association·R FogariG Derosa
Apr 21, 2012·Clinical Pharmacokinetics·Donald B Wiest, Jason S Haney
Feb 1, 2013·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Begoña Quintana-VillamandosEmilio Delgado-Baeza
Sep 3, 2013·Journal of Clinical and Diagnostic Research : JCDR·Kumar Haraprasad MisraY Roja Ramani
Jan 13, 2015·Saudi Journal of Kidney Diseases and Transplantation : an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia·Yasser El ShahawyGamal Mady

❮ Previous
Next ❯

Citations

Nov 22, 2017·PloS One·Begoña Quintana-VillamandosEmilio Delgado-Baeza
Apr 18, 2019·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Begoña Quintana-VillamandosMaria Carmen González

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiac Remodeling

Cardiac remodeling in response to a myocardial infarction is characterized by progressive ventricular dilatation, cardiac hypertrophy, fibrosis, and deterioration of cardiac performance. Discover the latest research on Cardiac Remodeling here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.